FeesSafety
Pluang+

Enlivex's Phase IIb knee osteoarthritis trial passes safety review, allowing continued patient enrollment.

Market News
18 Nov 2026, 15:00 WIB
GlobeNewsWire
View Source
Bullish
Enlivex's Phase IIb knee osteoarthritis trial passes safety review, allowing continued patient enrollment.

Enlivex Ltd. announced that the independent Data and Safety Monitoring Board (DSMB) completed a positive interim safety review of their Phase IIb clinical trial for Allocetra™, a treatment for primary age-related knee osteoarthritis. The review covered data from 85 patients and confirmed the safety profile supports continuing patient enrollment as planned. This trial aims to evaluate the efficacy and safety of Allocetra™ in patients aged 64 and older with moderate-to-severe knee osteoarthritis, with results expected to impact treatment options for this common and disabling condition. Enlivex plans to report topline data upon trial completion.

Enlivex's Phase IIb trial update offers context for health-sector investors. Of 150 health-sector US stocks on Pluang, 55 rose and 86 fell today. Notable movers include TNGX at USD 22.60 (+2.22%), CTXR at USD 0.53 (+2.16%) with 90% sell orders, and RLAY at USD 16.80 (+2.00%). Data is as of Nov 18, 2026 19:21 WIB.

More News

Lowe's beats Q3 earnings estimates and raises full-year sales outlook.

Lowe's beats Q3 earnings estimates and raises full-year sales outlook.

Lowe's reported adjusted earnings per share of $3.10, surpassing estimates of $2.88, and revenue of $22.80 billion, beating the $22.40 billion forecast. Comparable sales rose 1.8%, driven by strong online and professional services sales. The company ...

Company Fundamentals
Bullish
50 minutes ago
Major Memphis health system expands Daxor's blood volume testing to new outpatient site with 24-hour results.

Major Memphis health system expands Daxor's blood volume testing to new outpatient site with 24-hour results.

Daxor Corporation announced that a major Memphis health system has expanded its Blood Volume Analysis (BVA) program to an additional hospital outpatient site using Daxor’s ezBVA Lab service. This expansion allows the outpatient clinic to receive bloo...

Market News
Bullish
54 minutes ago
Microsoft shares drop 2.27% after global outages despite Oppenheimer's Outperform rating

Microsoft shares drop 2.27% after global outages despite Oppenheimer's Outperform rating

Microsoft's stock fell 2.27% to $506.24 following global outages affecting its Copilot, Teams, and Outlook services. The outages, attributed to server issues rather than cyberattacks, raised concerns amid broader software sector weakness. Oppenheimer...

Market News
Bearish
1 hour ago
Target posts strongest sales growth in 5 years, raises annual sales growth target to 6%.

Target posts strongest sales growth in 5 years, raises annual sales growth target to 6%.

Target Corporation reported earnings per share of $2.65, beating estimates of $2.08, and revenue of $27.1 billion, surpassing the $26.5 billion forecast. The company achieved its strongest quarterly sales growth in about five years, with net sales up...

Company Fundamentals
Bullish
1 hour ago
Aquestive Therapeutics to present at Piper Sandler Healthcare Conference on Dec 2, 2026

Aquestive Therapeutics to present at Piper Sandler Healthcare Conference on Dec 2, 2026

Aquestive Therapeutics announced its participation in the Piper Sandler 38th Annual Healthcare Conference from December 1-3, 2026, in New York City. CEO Daniel Barber will present on December 2 at 10:30 am ET, with one-on-one investor meetings schedu...

Market News
Neutral
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App